Zurich-Schlieren, Switzerland and Frankfurt am Main, Germany, December 2, 2020 - The University Hospital Frankfurt MVZ (Medical Outpatient Care Center) GmbH, and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, is made routinely available in Germany.
”Proclarix is an innovative new decision support tool to improve classification in prostate cancer diagnostics in men with elevated PSA levels. “We are excited to be the first clinical partner in Germany to offer this test”, said Prof. Dr. med. Peter Wild. “The procedure combines the ease-of-use and high acceptance for patients of a blood-based biomarker test with advanced bioinformatics to a risk score supporting physicians in patient management”
“We are delighted to have the University Hospital Frankfurt MVZ as a partner and expect that our collaboration will help to identify men suspected to have clinically relevant prostate cancer faster”, said Dr. med. Maurizio Ballerini, VP Market Development EMEA of Proteomedix. Dr. Ralph Schiess, CSO and co-founder of Proteomedix added: “The Proclarix’ risk score has been validated specifically in this challenging patient population so that it can help to reduce the number of biopsies avoiding invasive procedures, anxiety, discomfort, pain and complications. The clinical benefit of the Proclarix test was validated as part of an international multi-center study in which the Urology Clinic at the Frankfurt University Hospital, Prof. Dr. med. Felix Chun was also involved”.
Proclarix® is CE-IVD marked and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer.
About University Hospital Frankfurt MVZ GmbH
Located at Frankfurt, the MVZ is committed to advancing patient care by providing a comprehensive portfolio of histological, immunohistochemical and molecular analysis tools including genome profiles that enable doctors to make better clinical decisions every day. University Hospital Frankfurt MVZ GmbH covers a wide range of morphology- and molecular-based diagnostics. It was founded in 2019 and is certified according to DIN EN ISO 9001: 2008. In addition to cancer genomics, breast and prostate cancer diagnostics is one of the most important areas of expertise in order to ensure rapid and precise diagnosis at the highest level.
For further details, please contact:
Dr. med. Albrecht Hörlin, medical director and consultant, email@example.com, +49 69 6301 83666
Prof. Dr. med. Peter J. Wild, consultant, firstname.lastname@example.org, +49 69 6301 5364
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the European market early 2020. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
For further details, please contact:
Dr. med. Maurizio Ballerini, VP Market Development EMEA
email@example.com, +41 44 733 40 90